HER2 ADC Global Phase 3 trial FPI in HER2-Low BC

HER2 ADC (DB-1303) Phase 3 trial FPI in HER2+ BC

B7-H3 ADC (DB-1311) Global Phase 2 trials FPI

NMPA BTD for HER2 ADC (DB-1303)

FDA FTD & ODD for B7-H3 ADC (DB-1311)

FDA FTD for TROP2 ADC (DB-1305)

B7-H3 x PD-L1 BsADC (DB-1419) FDA IND approval

First-in-human study for Autoimmune ADC (DB-2304)

B7-H3 ADC (DB-1311) data read-out

DB-1303 FDA Fast Track Record Designation

DB-1303 Ph2 Clinical Trail 1st Patient in

DB1310 FDA IND Approval

DB1311 FDA IND Approval

DB1310 China IND Approval

DB1311 China IND Approval

Entered into an exclusive licensing and collaboration agreement with BioNTech, licensing out global rights to develop, manufacture, and commercialize of DB-1303 and DB-1311.

Lisensed BeOne global rights of DB-1312.

Licensed BioNTech the global rights to DB-1305, excluding the Greater China region

DB-1303 FDA Breakthrough Therapy Designation

DB-1303 Ph1 Clinical Trail 1st Patient in

DB-1303 China IND Approval

DB-1305 FDA IND Approval

DB-1305 China IND Approval

30 million USD B+ Round Financing

Suzhou R&D Center Launching

Successfully selected as a "Gazelle Cultivation Enterprise" in Suzhou

80 million USD B Round Financing

DB-1303 FDA IND Approval

Building DITAC TOP1i Platform

5 Million USD Seed Financing

22.5 Million USD

Thesmall molecule toxin ADC platform submitted the priority patent application. 

Dr. Zhongyuan Zhu has been awarded the Leading Talent in Science and Technology of Suzhou